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Gut microbiota has been implicated in major diseases affecting the human population and has
also been linked to triglycerides and high-density lipoprotein levels in the circulation. Recent
development in metabolomics allows classifying the lipoprotein particles into more details.
Here, we examine the impact of gut microbiota on circulating metabolites measured by
Nuclear Magnetic Resonance technology in 2309 individuals from the Rotterdam Study and
the LifeLines-DEEP cohort. We assess the relationship between gut microbiota and meta-
bolites by linear regression analysis while adjusting for age, sex, body-mass index, technical
covariates, medication use, and multiple testing. We report an association of 32 microbial
families and genera with very-low-density and high-density subfractions, serum lipid mea-
sures, glycolysis-related metabolites, ketone bodies, amino acids, and acute-phase reaction
markers. These observations provide insights into the role of microbiota in host metabolism
and support the potential of gut microbiota as a target for therapeutic and preventive
interventions.
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There is increasing interest in the role of the gut microbiotain the major diseases affecting the human population. For alarge part, these associations can be attributed to metabolic
and immune signals of the microbiota that enter the circulation1.
The gut microbiota has been implicated in obesity and diabetes2,
while recently it was also shown that the microbiota is also a
substantial driver of circulating lipid levels, including triglycerides
and high-density lipoproteins (HDL)3–5. The association with
low-density lipoprotein (LDL) cholesterol levels, the major target
for treatment of dyslipidemia, or total cholesterol was weaker
than the association with triglycerides and HDL3,4. Recent
development in metabolomics allows subclassifying the lipopro-
tein classes into more detail based on their particle size, com-
position, and concentration. Various studies further linked the
gut microbiota to various amino acids, which have been impli-
cated in diabetes and cardiovascular diseases6–10.
To provide novel insights into the relation of gut microbiota
and circulating metabolites, we perform an in-depth study of the
metabolome characterized by nuclear magnetic resonance (1H-
NMR) technology in two large population-based prospective
studies which have a rich amount of data on risk factors and
disease. We identify 32 microbial families and genera associated
with very-low-density and high-density subfractions, serum lipid
measures, glycolysis-related metabolites, amino acids, and acute-
phase reaction markers.
Results
Characteristics of study population. Our study is embedded
within the Rotterdam Study and LifeLines-DEEP cohort. The
Rotterdam Study is a prospective population-based cohort study
that started in 1990 among individuals from the well-deﬁned
district of Rotterdam11, while LifeLines-DEEP cohort is a sub-
cohort of LifeLines study, a prospective population-based cohort
study in the north of the Netherlands established in 200612.
Participants from the Rotterdam Study (n= 1390, mean age
56.9 ± 5.9, 57.5% women) were older compared to the partici-
pants from LifeLines-DEEP study (n= 915, mean age 44 ± 13.9,
58.7% women), while sex distribution in the two cohorts was
comparable.
Association of gut microbiota with circulating metabolites. The
results of association analysis between circulating metabolites
(Supplementary Data 1) and composition of gut microbiota
(Supplementary Data 2) are illustrated in Fig. 1. There were 32
microbial families and genera associated with various circulating
metabolites after adjusting for age, sex, body mass index (BMI),
medication use, including lipid-lowering medication, protein-
pump inhibitors, and metformin, technical covariates, and mul-
tiple testing (Fig. 1, Source Data). The variables corrected for in
the analysis were selected according to previous literature ﬁnd-
ings3,13. The multiple testing correction included Bonferroni
correction which was applied for the number of independent tests
in both metabolomics and gut microbiota datasets calculated by a
method of Li and Ji14 (0.05/(37 independent metabolite mea-
sures × 274 independent microbial taxa= 4.93 × 10−6). After
additional adjustment for smoking and alcohol intake, similar
association pattern was observed (Fig. 1b, Source Data). The
direction of effect size across the cohorts was generally con-
cordant (Supplementary Figs. 1–12 and Source Data).
We detected signiﬁcant associations between 18 microbial
families and genera and very-low-density (VLDL) particles of
various sizes (extra small, small, medium, large, very large, and
extremely large) and 22 microbial families and genera and HDL
particles (small, medium, large, and very large) (Source Data).
Abnormalities in VLDL particle distribution were reported to be
associated with metabolic disease etiology, cardiovascular dis-
eases, and type 2 diabetes7,15–17, while inverse association of very
large and large HDL particles and small and medium HDL
particles was reported in relation to disease risk7. There were 13
microbial families and genera associated with both VLDL and
HDL particles subclasses. For example, family Christensenellaceae
and genera Christensenellaceae R7 group, Ruminococcaceae
(UCG-005, UCG-003, UCG-002, and UCG-010), Marvinbryantia
and Lachnospiraceae FCS020 group were found to be associated
with VLDL particles of various sizes, small HDL particles and
triglycerides in medium HDL particles (Source Data), whereas
family Clostridiaceae1 and genus Clostridium sensu stricto 1 were
additionally associated with very large and large HDL particles
(Fig. 1b). Correlation analysis between these microbial taxa
revealed positive correlation between family Christensenellaceae,
Christensenellaceae R7 group genus, and Ruminococcaceae genera
(ρ ranged between 0.32 and 0.67) and within Ruminococcaceae
genera (ρ ranged between 0.46 and 0.77) (Supplementary Data 3).
These correlations are not unexpected and were reported by
previous studies18,19. Family Christensenellaceae was previously
associated with BMI20, genus Marvinbryantia was liked to bowel
dysfunction21, while family Clostridiaceae1 is involved in bile acid
metabolism and liked to BMI4,22. Of note is that the association
pattern of very large and large HDL particles, including
concentration of particles and its total lipids, cholesterol, free
cholesterol, and cholesterol esters was opposite compared to the
association pattern of small and medium HDL (Fig. 1).
In addition, we conﬁrmed previously reported association of
serum triglycerides and genus Ruminococcus gnavus, a gut
microbe linked to low gut microbial richness4,23. There were 15
microbial families and genera associated with serum triglycerides
(Fig. 1). The association pattern of serum triglycerides clustered
with triglycerides in small VLDL, LDL and HDL, medium HDL,
and cholesterol and cholesterol ester in medium VLDL
(Supplementary Fig. 13). Of 15 microbial families and genera
associated with serum triglycerides there were three microbial
taxa were also associated with VLDL, LDL, and HDL particles
and 9 were associated with VLDL and HDL particles (Supple-
mentary Fig. 14).
We also identiﬁed an association between family Lachnospir-
aceae and its genus Blautia with small HDL particles (Fig. 1b).
Genera from family Lachnospiraceae, one of the major taxonomic
groups of the human gut microbiota, have been associated with
the maintenance of gut health, and genus Blautia was associated
with obesity and reported to be involved in conversion of primary
bile acids into secondary bile acids24–26. Correlation coefﬁcient
between family Lachnospiraceae and genus Blautia that belongs
to this family was 0.82 (Supplementary Data 3). Family
Clostridiaceae1 and genus Clostridium sensu stricto 1 were
associated with diameter of both HDL and VLDL particles
(Fig. 1b). The VLDL diameter was further associated with family
Christensenellaceae and genera Christensenellaceae R7 group and
Ruminococcaceae UCG-002. Interestingly, diameter of HDL
particles was linked to cardiovascular disease 7,8.
Beyond the lipoprotein fractions, six microbial families and
genera were associated with fatty acids, including monounsatu-
rated (MUFA), saturated (SFA), and total fatty acids (TotFA),
while eight microbial families and genera were associated with
three other metabolites, including the ketone body acetate, amino
acid isoleucine, and acute-phase reaction marker glycoprotein
acetyl (mainly alpha 1) (Fig. 1b, Source Data). Genus Rumino-
coccaceae UCG-005 was associated with acetate, while family
Clostridiaceae1 and genera Clostridium sensu stricto 1 and
Ruminococcaceae UCG-014 showed association with isoleucine.
Interestingly, seven microbial families and genera were associated
with glycoprotein acetyls levels which are known to be associated
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with other common markers of inﬂammation and have been
implicated in inﬂammatory diseases and cancer7,8,27,28. Genera
from family Ruminococcaceae and Lachnospiraceae including
genus Blautia are reported to be involved in conversion of
primary bile acids into secondary bile acids and/or production of
short-chain fatty acids (SCFAs) 25,29,30.
Association of microbial diversity with circulating metabolites.
We next determined whether microbial diversity of gut micro-
biota was associated with lipoprotein particles or other metabo-
lites (Fig. 2). When adjusting for multiple testing and age, sex,
BMI, and medication use, the pattern emerging was that higher
microbiome diversity was signiﬁcantly associated with lower
levels of VLDL particles (small, large, medium, very large, and
extra-large), serum triglycerides, TotFA, MUFA, and SFA, and
increased levels of large and extra-large HDL particles and an
increased diameter of HDL (Fig. 2). As to the other metabolites,
higher microbiome diversity was signiﬁcantly associated with
lower levels of glycoprotein acetyl, alanine, isoleucine, and lactate
(Fig. 2). The strongest association was observed with triglycerides
in VLDL particles (p value= 8.48 × 10−10).
Discussion
We have examined the impact of gut microbiota on host circu-
lating metabolites in 2309 individuals from the Rotterdam Study
and LifeLines-DEEP cohort using 1H-NMR technology. We
identiﬁed associations between the gut microbiota composition
and various metabolites, including speciﬁc VLDL and HDL
lipoprotein subfractions; serum lipid measures, including trigly-
cerides and fatty acids; glycolysis-related metabolites, including
lactate; ketone bodies, including acetate; amino acids, including
alanine and isoleucine; and acute-phase reaction marker,
including the glycoprotein acetyl independent on age, sex, BMI,
and medication use. No associations were found to LDL sub-
fractions except for triglycerides in small LDL and glucose levels
measured by 1H-NMR.
Our results based on two large population-based studies
identiﬁed associations between the gut microbiota composition
and various lipoprotein particles. We observed an inverse asso-
ciation of family Christensenellaceae with VLDL particles of
various sizes, small HDL particles, and triglycerides in medium
HDL (Fig. 1b). The family Christensenellaceae was previously
linked to BMI and was associated with the reduced weight gain as
reported in the mice study in which germfree mice were
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Fig. 1 Results of association analysis between metabolites and microbial genera and families assessed by linear regression analysis (n= 2309).
Association results after adjustment for age, sex, body mass index, technical covariates, and medication use are displayed on panel (a), while association
results after additional adjustment for smoking and alcohol consumption are shown on panel (b). Metabolites are displayed on x-axis, whereas microbial
genera and families are shown on y-axis. Lipoprotein classes include very-low-density lipoprotein particles (VLDL), intermediate lipoprotein particles (IDL),
low-density lipoprotein particles (LDL), and high-density lipoprotein particles (HDL) of very low (XS), low (S), medium (M), large (L), very large (XL), and
extremely large (XXL) size. Blue color stands for inverse association. Red color denotes positive associations. Symbols on the plot represent the level of
signiﬁcance with hash denoting Bonferroni signiﬁcant associations at p value < 4.93 × 10−6. Source data are provided as a Source Data ﬁle.
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inoculated with lean and obese human fecal samples20. Further-
more, the family Christensenellaceae was reported to be the most
heritable microbial taxon in the study by Goodrich et al. inde-
pendently of the effect of BMI 20.
Interestingly, the gut microbiota composition showed asso-
ciation with VLDL and HDL particles of various sizes, however,
weak association has been found for LDL and IDL particles
suggesting that gut microbiota affects distinct classes of lipopro-
teins31. While VLDL particles of various sizes showed the same
pattern of association, differences were noticed between large,
medium, and small HDL particles suggesting that they are het-
erogeneous structures32. Small HDL particles are dense, protein-
rich, and lipid-poor, whereas large HDL particles are large, lipid-
rich particles33,34. Despite the fact that HDL is consistently
associated with a reduced risk of cardiovascular disease, the past
decade has seen major controversies on the clinical relevance of
HDL interventions. Most trials aiming to increase HDL levels in
the aggregate have been unsuccessful and were even stopped
because of adverse effects35,36. The heterogeneity of HDL classes
has been long recognized but can now be assessed on a large scale.
This compositional heterogeneity of HDL results in functional
heterogeneity such that small and large HDL particles are nega-
tively correlated and display inverse relationship with various
diseases, including cardiovascular disease, as reported pre-
viously32,33. As observed in our study the small HDL particles
were associated with genus Blautia and family Lachnospiraceae
and with lower diversity. Indeed the higher levels of small lipo-
protein particle concentration have previously been associated
with increased risk of stroke as reported in a recently published
study of Holmes et al., while the large and extra-large HDL
particles that were associated with family Clostridiacae1, genus
Clostridium sensu stricto1, and unknown family and genus, were
associated with decreased risk of cardiovascular disease and
stroke7. Interestingly, family Clostridiacae1 was previously
inversely correlated with BMI, serum triglycerides and is known
to be involved in bile acid metabolism 4,22.
Furthermore, we conﬁrmed the association of genus Rumino-
coccus gnavus group and serum triglycerides level37. Ruminococcus
gnavus group was previously associated with low gut microbial
richness23 and its abundance was higher in patients with athero-
sclerotic cardiovascular disease38. This genus showed positive cor-
relation with family Lachnospiraceae and inverse correlation with
genera from family Ruminococcaceae. This is in line with earlier
misclassiﬁcation as a Ruminococceae (now a Lachnospiraceae)39.
Microbial taxa that showed association with serum triglycerides
showed association with other lipoprotein particles as well (Sup-
plementary Fig. 13). However, we also observed microbial taxa that
were exclusively associated with VLDL (two microbial genera),
HDL (nine microbial genera and families) and LDL particles (one
genus) suggesting that lipoprotein particles are important and not
just a spillover effect of circulating triglycerides.
In addition to circulating lipids and lipoprotein particles, an
association was found between gut microbiota and ketone bodies
including acetate, amino acids including isoleucine, and acute-
phase reaction marker, including glycoprotein acetyls mainly
alpha 1. Circulating levels of acetate were speciﬁcally associated
with genus Ruminococcaceae UCG-005. Acetate is the most
common SCFA formed by bacterial species in the colon40. SCFA
can serve as an energy source, predominately via metabolism in
liver41,42. Previous studies suggested that acetate mediates a
microbiota-brain axis and promotes metabolic syndrome43. Cir-
culating levels of isoleucine, an essential branched-chain amino
acid, were inversely associated with three microbial taxa in our
sample. Recent studies reported association of circulating levels of
isoleucine with diabetes and cardiovascular disease8,44. Further-
more, isoleucine was reported to be negatively associated with
Christensenellaceae and microbial diversity and positively with
Blautia45. Even though we observe the same pattern of associa-
tion between isoleucine and these taxa, the associations did not
reach the signiﬁcance threshold. Also recently, a study focusing
on relation of fecal metabolites using mass spectroscopy (Meta-
bolon) and the gut microbiota was published6. Even though the
overlap of measured metabolites is limited, amino acids are
measured on both platforms. Other amino acids showed a strong
association with the gut microbiota but not isoleucine6. However,
the concentration of metabolite levels in feces and blood may
Legend
Cholesterol, fatty and amino acids,
inflammationVLDL HDL Glycerides
Microbial diversity 
RS
Microbial diversity 
LLD
Microbial diversity 
MA
XX
L–
VL
DL
–P
XX
L–
VL
DL
–L
XX
L–
VL
DL
–C
XX
L–
VL
DL
–P
L
XX
L–
VL
DL
–F
C
XL
–V
LD
L–
P
XL
–V
LD
L–
L
XL
–V
LD
L–
TG
XL
–V
LD
L–
C
XL
–V
LD
L–
PL
XL
–V
LD
L–
FC
XL
–V
LD
L–
CE
L–
VL
DL
–P
L–
VL
DL
–L
L–
VL
DL
–T
G
L–
VL
DL
–C
L–
VL
DL
–P
L
L–
VL
DL
–F
C
L–
VL
DL
–C
E
M
–V
LD
L–
P
M
–V
LD
L–
L
M
–V
LD
L–
TG
M
–V
LD
L–
C
M
–V
LD
L–
PL
M
–V
LD
L–
FC
M
–V
LD
L–
CE
S–
VL
DL
–P
S–
VL
DL
–L
S–
VL
DL
–T
G
S–
VL
DL
–P
L
S–
VL
DL
–F
C
XS
–V
LD
L–
TG
ID
L–
TG
S–
LD
L–
TG
XL
–H
DL
–P
XL
–H
DL
–L
XL
–H
DL
–C
XL
–H
DL
–P
L
XL
–H
DL
–F
C
XL
–H
DL
–C
E
L–
HD
L–
P
L–
HD
L–
L
L–
HD
L–
TG
L–
HD
L–
C
L–
HD
L–
PL
L–
HD
L–
FC
L–
HD
L–
CE
M
–H
DL
–T
G
S–
HD
L–
P
S–
HD
L–
L
S–
HD
L–
TG
S–
HD
L–
FC
VL
DL
–D
HD
L–
D
Se
ru
m–
TG
VL
DL
–T
G
HD
L–
TG
VL
DL
–C
HD
L2
–C
M
UF
A
SF
A
To
tF
A
Ac
Ac
e
La
c
Al
a lIe Gp
IDL LDL
Particle
size
Color key
Value
# - p-value < 1.35 × 10–3
–0.6 –0.4 –0.2 0 0.2 0.4 0.6
Fig. 2 Results of association analysis between metabolites and alpha diversity (n= 2309). Metabolites are displayed on x-axis whereas microbial
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differ. This is an important ﬁeld of future research. Lastly, gly-
coprotein acetyls, a composite marker that integrates protein
levels and glycosylation states of the most abundant acute phase
proteins in circulation46,47, was positively associated with genus
Blautia and Ruminococcus gnavus group and negatively associated
with microbial diversity. Genus Blautia is one of the microbial
taxa with substantial heritability in twin study20, and showed
strong association with the host genetic determinants which has
been associated with BMI and obesity26. Blautia was also reported
to be involved in conversion of primary bile acids into secondary
bile acids24–26. Glycoprotein acetyls are associated with other
common markers of inﬂammation46,47. Circulating level of gly-
coprotein acetyls have been implicated in inﬂammatory diseases
and cancer, and have been associated with mortality and cardi-
ovascular disease 7,8,27,28.
Potential mechanisms through which gut microbiota may
affect circulating lipid levels may involve bile acids and SCFAs.
Some of the microbial taxa identiﬁed in our study are involved in
conversion of primary to secondary bile acids and production of
SCFAs. Previous studies demonstrated that hepatic and/or sys-
temic lipid and glucose metabolism can be modulated by bacte-
rially derived bile acids absorbed into bloodstream31,48. Another
potential part of the biological basis for the association between
circulating lipid levels and microbial taxa may be through SCFAs.
SCFAs, such as butyrate, propionate, and acetate can affect lipid
biosynthesis, serve as important energy source, and regulate
inﬂammation and oxidative stress 49,50.
We also conﬁrmed association of microbial diversity and
serum triglycerides and provided insights into association with
HDL particles4. Previous studies reported positive association
between microbial diversity and HDL, however, advanced
analysis on lipoprotein subfractions revealed that large and
extra-large HDL particles were positivly associated with
microbial diversity while negative association was found for
medium and small HDL. Lower microbial diversity has been
found in autoimmune diseases, obesity, and cardiometabolic
conditions 51.
The strengths of our study are large sample size, population-
based study design, and harmonized analysis in participating
studies while correcting for factors such as use of medication and
BMI. Combing the data of two large population-based studies
allowed us to improve the statistical power of the study and
internally cross-check consistency of the ﬁndings. However, our
study has also limitations. When exploring circulating molecules,
we focused on metabolites measured by Nightingale platform
which covers a wide range of circulating compounds52. However,
these compounds represent a limited proportion of circulating
metabolites, therefore, future studies should focus on metabolites
detected by other more detailed techniques53. Further, the gut
microbial composition was determined from fecal samples. As gut
microbial composition varies throughout the gut with respect to
the anatomic location along the gut and at the given site, more
complete picture of the gut microbiota could be obtained by
getting samples from different locations along the intestines in the
future31,48. Furthermore, when exploring gut microbiota, we
focused on 16S rRNA sequencing. Even though broad shifts in
community diversity could be captured by 16S rRNA, metage-
nomics approaches provide better resolution and sensitivity54.
Additionally, the cross-sectional nature of our study failed to
track changes within each individual. Future studies should focus
on collecting stool and blood samples overtime for assessment of
longitudinal changes. Finally, although our analyses were adjusted
for various known confounders, residual confounding remains
possible.
To conclude, we found association between gut microbiota
composition and various circulating metabolites including
lipoprotein subfractions, serum lipid measures, glycolysis-related
metabolites, ketone bodies, amino acids, and acute-phase reaction
markers. Association between gut microbiota and speciﬁc lipo-
protein subfractions of VLDL and HDL particles provides
insights into the role of microbiota in inﬂuencing host lipid levels.
These observations support the potential of gut microbiota as a
target for therapeutic and preventive interventions.
Methods
Study population. Our study population included participants from two Dutch
population cohorts: Rotterdam Study and LifeLines-DEEP.
The Rotterdam Study is a prospective population-based cohort study that
includes participants from the well-deﬁned district of Rotterdam11. The aim of
Rotterdam Study is to investigate occurrence and determinants of diseases in
elderly11,55. The initial cohort included 7983 persons aged 55 years or older in 1990
(RS-I)11. The cohort was further extended in 2000/2001 by additional 3011
individuals, aged 55 years and older (RS-II), and in 2006/2008 by adding 3932
individuals, aged 45 years and older (RS-III)11. The participants underwent
interview at home and extensive set of examinations at the baseline11. Health
status, anthropometric and clinical variables were assessed in a standardized
manner by trained paramedical assistants and physicians in a specially built
research facility in the center of the district55. These examinations were repeated
every 3–4 years during the follow-up rounds in characteristics that could change
over time11. All participants provided written informed consent. The institutional
review board (Medical Ethics Committee) of the Erasmus Medical Center and by
the review board of The Netherlands Ministry of Health, Welfare, and Sports
approved the study.
The LifeLines-DEEP cohort is a sub-cohort of LifeLines study, a prospective
population-based cohort study in the north of the Netherlands established12. The
LifeLines cohort was established in 2006 among participants aged from 6 months
to 93 years in order to gain insights into the etiology of healthy aging56. At the
baseline, the participants ﬁlled in extensive questionnaires and visited one of the
LifeLines Research Sites twice for physical examinations56. After completion of
inclusion in 2013, the cohort includes 165,000 participants12. A follow-up
questionnaire was sent to each participant every 18 months and follow-up
measurements of the health parameters were performed every 5 years56. A subset of
approximately 1500 LifeLines participants aged 18–81 years was included in
Lifelines-DEEP56. These participants were examined more thoroughly, speciﬁcally
with respect to molecular data. Additional biological materials and information on
health status were collected for these participants56. The LifeLines-DEEP study is
approved by the Ethical Committee of the University Medical Center Groningen56.
All participants provided written informed consent.
Metabolite proﬁling. Quantiﬁcation of small compounds in fasting plasma sam-
ples was performed using 1H-NMR technology in both participating studies52,57,58.
Plasma samples of Rotterdam Study participants were collected in EDTA coated
tubes during the visit to the research facility in the center of the district11, while the
plasma samples of LifeLines-DEEP participants were collected during participant’s
second visit to the site56. Simultaneous quantiﬁcation of a wide range of meta-
bolites, including amino acids, glycolysis-related metabolites, ketone bodies, fatty
acids, routine lipids, and lipoprotein subclasses was done using the Nightingale
Health metabolomics platform (Helsinki, Finland). Detailed description of the
method can be found elsewhere57,59. In total there were 145 nonderived metabolite
measures quantiﬁed in absolute concentration units across the participating studies
(Supplementary Data 1).
Gut microbiota proﬁling. In order to study gut microbiota, fecal samples were
collected from participants of Rotterdam Study and LifeLines-DEEP study. Fecal
samples of Rotterdam Study participants were collected at home and sent through
regular email to the Erasmus MC. Upon arrival at Erasmus MC, samples were
stored at −20 °Csd an automated DNA isolation kit (Arrow; DiaSorin S.P.A.,
Saluggia, Italy) according to the manufacturer’s protocol. The V3 and V4 variable
regions of the 16S rRNA gene were ampliﬁed using the 319F (ACTCCTACGG-
GAGGCAGCAG) −806 (RGGACTACHVGGGTWTCTAAT) primer pair and
dual indexing and sequenced on Illumina MiSeq sequencer (MiSeq Reagent Kit v3,
2 × 300 bp)56,60. Fecal samples of Life-Lines-DEEP participants were collected at
home and stored immediately at −20 °C. After transport on dry ice, all samples
were stored at −80 °C. Aliquots were made, and DNA was isolated with the All-
Prep DNA/RNA Mini Kit (Qiagen; cat. #80204). Isolated DNA was sequenced at
the Broad Institute, Boston, using Illumina MiSeq paired-ends ﬂanking. Hyper-
variable region V4 was selected using forward primer 515F (GTGCCAGCMGC
CGCGGTAA) and reverse primer 806R (GGACTACHVGGGTWTCTAAT)56. A
direct classiﬁcation of 16S sequencing reads using RDP classiﬁer (2.12) and SILVA
16S database (release 128) were used to reconstruct taxonomic composition of
studied communities, with binning posterior probability cutoff of 0.861. All 16S
libraries were rareﬁed to 10,000 reads prior to taxonomy binning. This operational
taxonomic unit-independent approach was utilized to decrease domain-dependent
bias. The microbial Shannon diversity index was calculated on taxonomic level of
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genera, using vegan package in R (https://www.r-project.org/). Gut microbiota
composition dataset included 1427 participants from the RS-III cohort that par-
ticipated in the second examination round at the study center. Metabolite mea-
surements were available for 1390 Rotterdam Study (RSIII-2) participants. In the
LifeLines-DEEP study, gut microbiota composition dataset, included 1186 parti-
cipants; from them the metabolite measurements were available for 915
participants.
Statistical analysis. Prior to the analysis, all metabolites were natural logarithmic
transformed to reduce skewness of traits distributions. To deal with values under
detectable limit (reported as zeros) we added half of the minimum detectable value
of the corresponding metabolite prior to transformation. The metabolite measures
were then centered and scaled to mean of 0 and standard deviation of 1. Similarly,
to reduce skewness of the distribution of microbial taxa counts, we ﬁrst added 1 to
all taxonomy counts and then performed natural log transformation. Correlation
between microbial taxa was assessed by Spearman correlation.
The relationship between metabolites and microbial taxa was assessed by linear
regression analysis while adjusting for age, sex, BMI, technical covariates including
time in mail and DNA batch effect (only in Rotterdam Study) and regular
medication use (yes/no) including lipid-lowering medication (395 users in
Rotterdam Study and 34 in Lifelines-DEEP), proton-pump inhibitors (258 users in
Rotterdam Study and 72 in Lifelines-DEEP), and metformin (67 users in
Rotterdam Study and 8 in Lifelines-DEEP). The analyses were further adjusted for
smoking status deﬁned as never, former or current and daily alcohol consumption
(in grams per day). Participants using antibiotics were excluded from the analysis.
The summary statistics of participating studies were combined using inverse
variance-weighted ﬁxed-effect meta-analysis using rmeta package in R (https://
cran.r-project.org/web/packages/rmeta/index.html, https://www.r-project.org/). In
total, 145 overlapping metabolite measures and 345 overlapping microbial taxa at
taxonomic level of family and genera were tested for association. These microbial
taxa were present in at least three samples. As measurements in both metabolomics
and gut microbiota datasets are highly correlated, we used a method of Li and Ji14
to calculate a number of independent tests. There were 37 independent tests among
the metabolite measures and 274 independent tests among microbial taxa. The
signiﬁcance threshold was thus set at 0.05/ (37 × 274)= 4.93 × 10−6.
The relationship between metabolites and microbial diversity was also assessed
by linear regression analysis while adjusting for age, sex, BMI, technical covariates,
and medication use (lipid-lowering medication, protein-pump inhibitors, and
metformin) in each of the participating studies and summary statistics results were
combined using inverse variance-weighted ﬁxed-effect meta-analysis using rmeta
package in R.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
All relevant data supporting the key ﬁndings of this study are available within the article
and its supplementary information ﬁles. Data underlying Fig. 1 and Supplementary
Figs. 1–13 are provided as Source Data ﬁle. Other data are available from the
corresponding author upon reasonable requests. Due to ethical and legal restrictions,
individual-level data of the Rotterdam Study (RS) cannot be made publicly available.
Data are available upon request to the data manager of the Rotterdam Study Frank van
Rooij (f.vanrooij@erasmusmc.nl) and subject to local rules and regulations. This includes
submitting a proposal to the management team of RS, where upon approval, analysis
needs to be done on a local server with protected access, complying with GDPR
regulations. The LifeLines-DEEP metagenomics sequencing data are available at the
European Genome-phenome Archive under accession EGAS00001001704.
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